Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q2 2025 value amounting to $126.0 million.

  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) rose 171.1% to $126.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $126.0 million, marking a year-over-year increase of 171.1%. This contributed to the annual value of $123.9 million for FY2024, which is 440.44% up from last year.
  • Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $126.0 million in Q2 2025, which was up 171.1% from $125.5 million recorded in Q1 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $126.0 million during Q2 2025, and registered a low of $80654.0 during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $112.4 million (2022), whereas its average is $76.4 million.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 9989.32% in 2021 and then surged by 11179721.47% in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $84.4 million in 2021, then increased by 25.7% to $106.1 million in 2022, then grew by 11.84% to $118.7 million in 2023, then increased by 4.4% to $123.9 million in 2024, then grew by 1.71% to $126.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $126.0 million for Q2 2025, versus $125.5 million for Q1 2025 and $123.9 million for Q4 2024.